US2015051256A1PendingUtilityA1

Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent

Assignee: TAKEDA PHARMACEUTICALPriority: Jan 27, 2010Filed: Oct 28, 2014Published: Feb 19, 2015
Est. expiryJan 27, 2030(~3.5 yrs left)· nominal 20-yr term from priority
Inventors:Naomi Kitamoto
A61P 43/00A61P 35/00A61P 39/00A61P 25/00A61P 25/02A61K 31/69A61K 31/4196A61K 45/06A61K 31/41A61K 31/216C07D 275/06C07C 311/28C07D 309/28A61K 31/337C07D 249/06C07D 257/04A61K 31/4192A61K 31/282A61K 31/428A61K 31/4545A61K 31/351A61K 31/235
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.

Claims

exact text as granted — not AI-modified
1 . A method for suppressing a peripheral nerve disorder induced by an anti-cancer agent, which comprises administering a compound represented by the formula (II): 
       
         
           
           
               
               
           
         
         wherein 
         R 1′  is 
         (1) an aliphatic hydrocarbon group optionally having substituent(s), 
         (2) an aromatic hydrocarbon group optionally having substituent(s), 
         (3) a heterocyclic group optionally having substituent(s), 
         (4) a group represented by the formula: —OR 1a′  wherein R 1a′  is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), or 
         (5) a group represented by the formula: 
       
       
         
           
           
               
               
           
         
         wherein R 1b′  and R 1c′  are the same or different and each is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), 
         X is methylene, NH, a sulfur atom or an oxygen atom, 
         Y is methylene optionally having substituent(s) or NH optionally having substituent(s), 
         ring A′ is a 5- to 8-membered ring optionally having 1 to 4 substituents selected from the group consisting of 
         (i) an aliphatic hydrocarbon group optionally having substituent(s), 
         (ii) an aromatic hydrocarbon group optionally having substituent(s), 
         (iii) a group represented by the formula: —OR 2′  wherein R 2′  is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), and 
         (iv) a halogen atom, 
         Ar′ is an aromatic hydrocarbon group optionally having substituent(s), 
         a group represented by the formula: 
       
       
         
           
           
               
               
           
         
         is a group represented by the formula: 
       
       
         
           
           
               
               
           
         
         s is an integer of 0 to 2, 
         t is an integer of 1 to 3, and 
         the total of s and t is 4 or less; 
         provided that when X is methylene, then Y should be methylene 
         optionally having substituent(s), 
         or a salt thereof or a prodrug thereof.

Join the waitlist — get patent alerts

Track US2015051256A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.